{
  "docId": "019de075-f745-744d-a2c3-62fcecd316e9",
  "docSlug": "352ee416e6a97a9b39e1309fafdab0f3",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 38,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": "The slide uses a Gantt-style visualization to show clinical trial stages for multiple drug candidates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/5",
  "deckHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9",
  "deckJsonHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json",
  "deckAnchorHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.4,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Clinical trial progress bars",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18b471da-94d2-477b-bc90-9973b5334292",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.78,
        "w": 0.96,
        "x": 0.02,
        "y": 0.13
      },
      "kind": "table",
      "text": "Pipeline table with columns: Olvi-Vec, Human Health, Design, Preclinical, Phase 1, Phase 2, Phase 3, Collaborators",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bff43e69-8656-4191-b19f-cc4809b74cb6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.85,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Diversified Designs and Indications Exploit Competitive Advantages",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b16e4d80-faa4-4b25-b972-caae9479afd1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "597ce2da-bc5d-4aa2-9957-2231e7cbb8a0",
      "evidence": "Pipeline table with columns: Olvi-Vec, Human Health, Design, Preclinical, Phase 1, Phase 2, Phase 3, Collaborators",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "81f19533-f421-49a4-b4fb-89aacca1b0e9",
      "evidence": "The slide uses horizontal bars to represent the duration and status of clinical trials across different phases.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 4,
      "beatId": "fdbee508-b41b-482b-8db8-5d1f0a14e7b6",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 4-9 emphasize the complications and challenges of current treatments, including resistance and refractoriness.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "38515402-0f9a-4e9b-81f7-00348eb645d5",
      "evidence": "The deck highlights the limitations and challenges of current treatments, implicitly raising the question of what if we don't innovate.",
      "position": 0,
      "objective": "What if we don't adopt a new approach to oncolytic immunotherapy?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}